Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/
- PDF / 1,838,958 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 75 Downloads / 206 Views
Evaluation of bone metastasis burden as an imaging biomarker by quantitative single‑photon emission computed tomography/ computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study Kazuki Motegi1,2 · Norikazu Matsutomo2,3 · Tomoaki Yamamoto2,3 · Mitsuru Koizumi1 Received: 14 January 2020 / Revised: 6 June 2020 / Accepted: 8 June 2020 © Japanese Society of Radiological Technology and Japan Society of Medical Physics 2020
Abstract Metabolic bone volume (MBV), standardized uptake value (SUV), and total bone uptake (TBU) are new imaging biomarkers for quantitative bone single-photon emission computed tomography/computed tomography. The purpose of this study was to validate the quantitative accuracy and utility of MBV, S UVmean, and TBU for the assessment of bone metastases in prostate cancer. We used a bone-specific phantom with four hot spheres (φ = 13, 17, 22, 28 mm) filled with different Tc-99 m activities to simulate uptake ratios of 3 and 7, corresponding to normal and metastatic values. We calculated the error ratio (%Error) by comparing MBV, SUVmean, and TBU with true values for various parameters, including bone lesion size, uptake ratio, and SUV cut-off level. Differences for MBV, SUVmean, TBU, and bone scan index (BSI) were calculated to verify their utility in assessing bone metastases. Receiver-operating characteristic curve (ROC) analysis was performed to calculate the area under the curve (AUC) for each biomarker. MBV, SUVmean, and TBU were affected by lesion size, uptake ratio, and SUV cut-off level; however, TBU demonstrated the most stable %Error. The TBU %Error was within 15% in spheres 17 mm or larger when the SUV cut-off level was 7, regardless of the uptake ratio. The ROC analyses revealed the AUCs of BSI (0.977) and TBU (0.968). Additionally, TBU was able to assess bone metastasis when BSI provided false-negative results, but TBU also provided false-positive results by degenerative changes. The synergy between TBU and BSI could potentially improve diagnostic accuracy. Keywords Quantitative SPECT/CT · Bone scintigraphy · Prostate cancer · Tumor response
* Kazuki Motegi [email protected] Norikazu Matsutomo [email protected]‑u.ac.jp Tomoaki Yamamoto [email protected]‑u.ac.jp Mitsuru Koizumi [email protected] 1
Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3‑8‑11 Ariake, Koto‑ku, Tokyo 135‑8550, Japan
2
Graduate School of Health Sciences, Department of Medical Radiological Technology, Faculty of Health Sciences, Kyorin University, A‑420, 5‑4‑1 Shimorenjaku Mitaka‑shi, Tokyo 181‑8612, Japan
3
Department of Medical Radiological Technology, Faculty of Health Sciences, Kyorin University, 3‑8‑11 Ariake, Koto‑ku, Tokyo 135‑8550, Japan
1 Introduction Bone scintigraphy is the standard method for diagnosing osteoblastic bone metastasis, which is common in prostate cancer, although various other imaging methods are available [1]. The European Association of Nuclear Medicine
Data Loading...
